Industry: the pharmaceutical industry will change greatly in the future. What is the way to deal with it?

[pharmaceutical network market analysis] "in the current pharmaceutical pattern, of the more than 5000 pharmaceutical enterprises in China, less than 700 are profitable and optimistic about 2020, while less than 300 are able to meet future challenges." Industry insiders said that due to the continuous impact of policies such as expanding with volume procurement, the pharmaceutical industry will change greatly in the future, and a number of pharmaceutical enterprises will inevitably be eliminated In this context, enterprises need to find ways to deal with the change, in order to accept more challenges Photo source: the "4 + 7" volume procurement of pharmaceutical network will be launched in an all-round way "4 + 7" drug centralized procurement pilot in the pharmaceutical industry has achieved better results than expected since it was fully implemented on April 1, 2019, and the burden of drug use for patients in the pilot area has been greatly reduced In order to let the people in non pilot areas also use the high quality and low price related drugs as soon as possible, on September 1, 2019, Shanghai Sunshine pharmaceutical purchase network officially linked the centralized drug purchase document in alliance area, which made it clear that on the basis of the implementation of the centralized purchase results in 4 + 7 cities and provinces that have followed up and implemented, the state organized the relevant regions to form an alliance, and carried out the centralized drug purchase in cross regional alliance in accordance with the law and regulations Purchase A total of 25 provinces participated in the pilot expansion According to the results, 77 enterprises participated in the declaration, 45 enterprises planned to be selected, with a winning rate of more than 50% The number of enterprises planned to be selected and the price level of enterprises planned to be selected met the expectation as a whole In the pilot expansion, the "consistency evaluation" will be regarded as the qualification standard for generic drugs to participate in the centralized volume purchase If there are more than three manufacturers that have passed the consistency evaluation for the same kind of drugs, the products that have not passed the consistency evaluation will no longer be selected, and the market capacity will be released to the evaluated drugs After the pilot expansion, 25 drugs will be purchased in volume throughout the country It can be seen that pharmaceutical enterprises will face higher requirements in terms of product quality, capacity supply and cost control, and the pressure of competition will also be greater Now, the second batch of volume procurement has been started, and volume procurement will become the normal The industry expects that in the next 5-7 years, 4 + 7 will be rolled out in an all-round way or the industry will be optimized and restructured, which is a big challenge for pharmaceutical enterprises "One vote system" or implementation of the recent industry news that "one vote system" is coming! The implementation of "one vote system" means that the functions of pharmaceutical wholesale enterprises are greatly reduced, and the life of pharmaceutical wholesale enterprises will be more difficult In fact, from the documents issued by some provinces in recent years, we can see the similar shadow of "one vote system"   For example, in November 2017, Anhui Province issued the implementation opinions of "two ticket system" for medical consumables procurement of public medical institutions in Anhui Province (Trial), which made clear provisions for the implementation of two ticket system for medical consumables, and encouraged "one ticket system"; in 2019, Hunan issued the document that centralized procurement should be carried out for 54 antibacterial drugs, among which in terms of drug distribution, the winning drugs are required to be purchased by drugs In 2019, the notice on further promoting the experience of deepening the reform of medical and health system in Fujian Province and Sanming City mentioned that the comprehensive medical reform pilot province should promote the medical insurance agency to directly settle the payment with the pharmaceutical production or circulation enterprises, and other provinces should We should also actively explore In addition, the 4 + 7 policy requires medical institutions to settle accounts with enterprises in time, and the medical insurance association prepays at least 30% of the purchase money to medical institutions, which may further promote the development of one vote system At the same time, the new version of drug management law has been implemented It can be seen that the enterprises with drug approval documents are basically MAH (drug listing license holder), and they can directly sell one ticket to the end Some insiders predict that the one vote system may be implemented before and after the implementation of free medical treatment by the whole people in 2023, which is undoubtedly a big impact for pharmaceutical wholesale enterprises How should pharmaceutical companies deal with it? In many of the above medical reform policies, the pharmaceutical industry will undoubtedly change According to industry estimates, at present, thousands of pharmaceutical enterprises will be able to meet the challenges and leave only 200-300 large enterprises in the next decade after industry integration So, how should pharmaceutical companies deal with it? The industry believes that the main way to deal with the change is to create the value of patients, doctors and customers First, in terms of creating value for patients, pharmaceutical enterprises should make products further return to patient value, strengthen innovation, operate in compliance, and develop more drugs with clinical value, good efficacy and reasonable price, so as to gain the trust of patients It is worth mentioning that the service ability of pharmaceutical enterprises as product side is weak, and they can not reach the real medical needs of patients It is reported that at present, some pharmaceutical enterprises provide some patient and patient education tools around the products, aiming to clarify the use methods and precautions of a certain drug This kind of tools often cooperate with a kind of drug, which is very targeted, but not universal What's more, it's the way that pharmaceutical enterprises do market education for drugs At present, the pharmaceutical research and development industry committee of China Association of foreign funded enterprises has issued a consensus framework, and the signed institutions have been extended to hospitals Through the combination of medicine and medicine, patients are the center, and the whole process from production and circulation to treatment provides better services for patients Second, in terms of creating value for doctors, because doctors are a busy profession, the opportunity for pharmaceutical companies lies in providing doctors with valuable information resources, so as to reduce the burden of doctors The industry believes that in the current social environment and the situation doctors are facing, pharmaceutical companies can do more to make doctors easier to find the medical and pharmaceutical information they need Third, in terms of creating customers, the industry believes that the digital revolution has had a huge impact on the way pharmaceutical companies interact with customers However, to provide customers with great value is the key point, which requires thinking and decision-making at the organizational strategic level of pharmaceutical enterprises, which is also the key to the long-term survival and development of pharmaceutical enterprises.